Back to Search Start Over

Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study.

Authors :
Wang R
Wang W
Ma K
Duan X
Wang F
Huang M
Zhang W
Liang T
Source :
Frontiers in pharmacology [Front Pharmacol] 2020 Aug 19; Vol. 11, pp. 1252. Date of Electronic Publication: 2020 Aug 19 (Print Publication: 2020).
Publication Year :
2020

Abstract

Objective: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC C <subscript>min</subscript> ) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC C <subscript>min</subscript> post-ERCP and related factors.<br />Methods: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC C <subscript>min</subscript> measures). The absolute difference and the variation extent in TAC C <subscript>min</subscript> pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared.<br />Results: The TAC C <subscript>min</subscript> in LT patients significantly increased in the first three days post-ERCP ( p <0.05) and increased by more than 20% in 18 out of 26 (69.2%) patients. The mean extent of variation in TAC C <subscript>min</subscript> was 45.1% (95% confidence interval [CI]: 28.3-81.3%) and 31.4% (95% CI: 9.7-53.1%) on days 1 and 3 post-ERCP, respectively. The increasing TAC C <subscript>min</subscript> gradually returned to baseline within a week ( p >0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher ( p <0.05) in patients with obvious variation in TAC C <subscript>min</subscript> . The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant.<br />Conclusion: The TAC C <subscript>min</subscript> significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors.<br /> (Copyright © 2020 Wang, Wang, Ma, Duan, Wang, Huang, Zhang and Liang.)

Details

Language :
English
ISSN :
1663-9812
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
32973503
Full Text :
https://doi.org/10.3389/fphar.2020.01252